CHICAGO, April 6 /PRNewswire/ -- NanoInk, Inc., today announced that the
Company's President and Chief Executive Officer, Dr. Cedric Loiret-Bernal will
be a featured guest speaker at the BIO 2006 Annual International Convention
being held in Chicago.
Logo: http://www.newscom.com/cgi-bin/prnh/20030418/NANOLOGO )
Dr. Loiret-Bernal, a leading expert on nanoencryption, will speak about
the Company's Nanoencryption(TM) technology and its use by pharmaceutical
customers and DPN(R) technology for bio-nanoarrays. The presentation will
begin at 9:30 a.m. CDT on Wednesday, April 12, 2006, in Room C, McCormick
Place South, Level 3, Exhibit Hall A of the McCormick Place Convention Center.
The McCormick Place Convention Center is located at 2301 South Lake Shore
Drive, Chicago, IL.
Dr. Loiret-Bernal is the former Chief Executive Officer and co-founder of
GeneProt, Inc., and has also held many other senior positions in the
pharmaceutical and biomedical industries at Abbott Laboratories, Haemonetics,
and Porges-Synthelabo. Dr. Loiret-Bernal holds a doctor of medicine degree,
summa cum laude, from the University of Bordeaux and has an MBA degree from
the J.L. Kellogg School of Management, Northwestern University.
"BIO 2006 is a wonderful opportunity to share the potential value of our
proprietary Nanoencryption(TM) technology that helps prevent counterfeit and
illegal pharmaceuticals from entering the global markets," said Dr.
Loiret-Bernal. "I will also discuss the potential of our DPN(R) technology
that enables the deposition of a variety of biomolecules for the development
Nanoencryption(TM) technology is the one-stop, deeply covert encryption
and authentication solution to prevent counterfeit pharmaceuticals from
entering the market. Counterfeit pharmaceuticals can be easily identified by
the absence of special coded nanoencryption. During the authentication
process, illegal products are flagged as mismatches and removed from the
supply chain. Using NanoInk's proprietary technology, pharmaceutical
manufacturers and enforcement agencies can identify and significantly reduce
counterfeiting and illegal diversion.
NanoInk's Scientific Founder, Chad A. Mirkin, Ph.D., Director of the
International Institute of Nanotechnology, George B. Rathmann Professor of
Chemistry, Professor of Medicine, Professor of Material Sciences &
Engineering, Northwestern University, will discuss his most recent DPN(R)
research work at The Illinois Pavilion, McCormick Place Convention Center, at
3 pm CDT, on Tuesday, April 11, 2006. During this presentation, his work will
be recognized with an award presented by the Illinois Biotech Organization
NanoInk, Inc. is an emerging growth technology company specializing in
nanometer-scale manufacturing and applications development for the lifescience
and semiconductor industries. With DPN(R), a patented and proprietary
nanofabrication technology that allows for unmatched flexibility, accuracy and
also its high-resolution Nanoencryption(TM) technology, NanoInk is able to
offer its pharmaceutical customers innovative solutions to fight
counterfeiting and illegal diversion of blockbuster pharmaceutical products.
Other key applications include nanoscale additive repair, and nanoscale rapid
prototyping. Located in the new Illinois Science + Technology Park, north of
Chicago, NanoInk currently has over 100 patents and patent applications filed
worldwide and has licensing agreements with Northwestern University, Stanford
University, and the University of Illinois at Urbana-Champaign. For more
information on products and services offered by NanoInk, Inc., see
SOURCE NanoInk, Inc.